Interstitial Cystitis/Bladder Pain Syndrome: What Today’s Urologist Should Know

Adelugba, Ifeoluwa; Siddiqui, Sana; Aziz, Asef; De, Elise; Wolff, G

doi:10.1007/s11884-022-00676-1

Cited by 4 publications

(3 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17 The psychological therapies for IC/BPS include stress reduction, lifestyle modification, behavior modification, and cognitive behavioral therapy (CBT); a multidisciplinary approach is optimal in achieving symptom control. 34 Furthermore, IC/BPS is most prevalent in middle-aged women and even in men. IC/BPS symptoms do not only result from the urinary bladder but also have multiple etiologies from chronic pain, daily-living menace of lower urinary tract symptoms (LUTS), and even holistic biopsychosocial duress.…”

Section: Pathophysiology and Multidisciplinary Approach Of Ic/bpsmentioning

confidence: 99%

“…Current treatment guidelines recommend the physical domain treatment for IC/BPS with (1) replenishment of the glycosaminoglycan (GAG) layer to control urothelial defects, (2) administration of amitriptyline or imipramine to inhibit neurological hyperactivity, (3) suppression of allergies by antihistamines, and (4) administration of nonsteroidal anti‐inflammatory drugs for pain control 17 . The psychological therapies for IC/BPS include stress reduction, lifestyle modification, behavior modification, and cognitive behavioral therapy (CBT); a multidisciplinary approach is optimal in achieving symptom control 34 …”

Section: Pathophysiology and Multidisciplinary Approach Of Ic/bpsmentioning

confidence: 99%

See 1 more Smart Citation

Multimodal therapies and strategies for the treatment of interstitial cystitis/bladder pain syndrome in Taiwan

Yu,

Kuo

2023

LUTS

View full text Add to dashboard Cite

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic disease characterized by bladder pain, frequency, and nocturia. The most common pathologies include chronic inflammation and bladder urothelium dysfunction. According to the bladder condition with or without Hunner's lesions, IC/BPS can be divided into “IC” in patients with Hunner's lesion (HIC) and “BPS” in those without Hunner's lesion (NHIC). Previous studies have reported greater central sensitization and interorgan cross‐talk in patients with NHIC. Multimodal treatments have been recommended in clinical guidelines under the biopsychosocial model. The bladder–gut–brain axis has also been speculated, and multimodal therapies are necessary. Unfortunately, currently, no treatment has been reported durable for IC/BPS. Patients with IC/BPS usually experience anxiety, depression, holistic physical responses, and even threats to social support systems. The lack of durable treatment outcomes might result from inadequate diagnostic accuracy and differentiation of clinical phenotypes based on the underlying pathophysiology. Precision assessment and treatment are essential for optimal therapy under definite IC/BPS phenotype. This article reviewed currently available literature and proposed a diagnosis and treatment algorithm. Based on bladder therapy combined with suitable physical and psychological therapies, a well‐grounded multimodal therapy and treatment algorithm for IC/BPS following a diagnostic protocol are indispensable.

show abstract

Section: Pathophysiology and Multidisciplinary Approach Of Ic/bpsmentioning

confidence: 99%

Section: Pathophysiology and Multidisciplinary Approach Of Ic/bpsmentioning

confidence: 99%

Multimodal therapies and strategies for the treatment of interstitial cystitis/bladder pain syndrome in Taiwan

Yu,

Kuo

2023

LUTS

View full text Add to dashboard Cite

show abstract

“…Interstitial cystitis/bladder pain syndrome (IC/BPS) is a complicated and puzzling health condition. Patients with IC/BPS experience pain in the bladder or pelvic cavity and lower urinary tract symptoms, including frequent urination, urgency, and nocturia [ 1 ]. Although IC/BPS is not lethal, the pain and urinary symptoms significantly impact the patient’s quality of life and mental health.…”

Section: Introductionmentioning

confidence: 99%

Intravesical Botulinum Toxin Injection Plus Hydrodistention Is More Effective in Patients with Bladder Pain-Predominant Interstitial Cystitis/Bladder Pain Syndrome

Yu,

Jhang,

Kuo

2024

Toxins

View full text Add to dashboard Cite

Intravesical botulinum toxin A (BoNT-A) injections are included in the interstitial cystitis/bladder pain syndrome (IC/BPS) treatment guidelines. However, the IC phenotype suitable for treatment with BoNT-A has not been clarified. Therefore, we identified the factors influencing treatment outcomes for intravesical BoNT-A injections in patients with non-Hunner IC/BPS (NHIC). This retrospective study included patients with NHIC who underwent 100 U BoNT-A intravesical injections over the past two decades. Six months after treatment, treatment outcomes were assessed using the Global Response Assessment (GRA). Outcome endpoints included GRA, clinical symptoms, urodynamic parameters, urine biomarkers, and the identification of factors contributing to satisfactory treatment outcomes. The study included 220 patients with NHIC (42 men, 178 women). The satisfactory group (n = 96, 44%) had significantly higher pain severity scores and IC symptoms index, larger maximum bladder capacity (MBC), and lower 8-isoprostane levels at baseline. Logistic regression revealed that larger MBC (≥760 mL) and bladder pain predominance were associated with satisfactory outcomes after BoNT-A injection. Subjective parameters and pain severity scores improved significantly in patients with bladder pain-predominant IC/BPS after BoNT-A injection. Thus, NHIC patients with bladder or pelvic pain are more likely to experience satisfactory outcomes following intravesical BoNT-A injections.

show abstract

Progress in the Diagnosis and Treatment of Different Types of Cystitis

武

2024

ACM

View full text Add to dashboard Cite

Interstitial Cystitis/Bladder Pain Syndrome: What Today’s Urologist Should Know

Cited by 4 publications

References 79 publications

Multimodal therapies and strategies for the treatment of interstitial cystitis/bladder pain syndrome in Taiwan

Multimodal therapies and strategies for the treatment of interstitial cystitis/bladder pain syndrome in Taiwan

Intravesical Botulinum Toxin Injection Plus Hydrodistention Is More Effective in Patients with Bladder Pain-Predominant Interstitial Cystitis/Bladder Pain Syndrome

Progress in the Diagnosis and Treatment of Different Types of Cystitis

Contact Info

Product

Resources

About